You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

CAR T-Cell Therapy in Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy that uses the body's own immune system to target cancer cells. The therapy involves engineering the patient's own T cells to produce synthetic molecules on their surface that can specifically recognize and attack cancer cells. Clinical Advances in CAR T-Cell Therapy in Multiple Myeloma provides education on the rationale, methodology, and evidence for this therapy, and its implications for clinical practice.

Supported by an independent educational grant from

CME Activities

Polling Question

Related Resources

Steering Committee


Philippe Moreau, MD

Steering Committee Chair

University Professor of Clinical Hematology
Head, Hematology Department
University Hospital of Nantes
Nantes, France


Hermann Einsele, MD, FRCPC

Professor, Director
University Hospital Wuerzburg
Wuerzburg, Bavaria, Germany


Nikhil C. Munshi, MD

Kraft Family Chair and Professor of Medicine
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States


Noopur Raje, MD

Director, Center for Myeloma Massachusetts General Hospital Boston, Massachusetts, United States


Paula Rodriguez Otero, MD, PhD

Consultant Clinica Universidad de Navarra University of Navarra Pamplona, Navarra, Spain


Nina F. Shah, MD

Associate Professor of Medicine
University of California San Francisco
United States